

## Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

## Dermavant at-a-glance

- A biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, CA, Raleigh-Durham, NC, and Dallas, TX

## About Dermavant

### A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, that represent new treatment categories and address some of the greatest challenges providers and patients encounter.

The company recently launched its first product, VTAMA® (tapinarof) cream, 1%, for the treatment of plaque psoriasis in adults, one of the largest growing immuno-dermatology markets. The company's robust immuno-dermatology pipeline also includes both late-stage and early-development product candidates that target specific unmet needs in another of the largest growing immuno-dermatology markets and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.

Dermavant is also developing tapinarof cream, 1%, (DMVT-505), as a novel small molecule therapeutic aryl hydrocarbon receptor modulating agent topical cream of plaque psoriasis in adults and atopic dermatitis, which affects approximately 26 million people in the United States.

## Management team

### Todd Zavodnick

Chief Executive Officer

### Philip M. Brown, MD, JD

Chief Medical Officer

### Chris Chapman

Chief Commercial Officer

### David Rubenstein, MD, PhD

Chief Scientific Officer

### Michael Swartzburg

Chief Financial Officer

### Christopher Van Tuyl, JD

Chief Legal Officer

### IMPORTANT SAFETY INFORMATION

**Indication:** VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. **Adverse Events:** The most common adverse reactions (incidence  $\geq$  1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

# Dermavant has four product candidates in development addressing:

Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne

PRODUCT CANDIDATE	POTENTIAL INDICATION	STAGE OF DEVELOPMENT				
		Preclinical	Phase 1	Phase 2	Phase 3	FDA Review
<p><b>Tapinarof (DMVT-505)</b> A topical, therapeutic AhR modulating agent, inhibiting several proinflammatory factors</p>	Atopic Dermatitis	[Progress bar: Preclinical, Phase 1, Phase 2]			[Progress bar: Phase 3]	[Progress bar: FDA Review]
<p><b>Cerdulatinib (DMVT-502)</b> A topical dual JAK/Syk inhibitor</p>	Vitiligo	[Progress bar: Preclinical, Phase 1]		[Progress bar: Phase 2, Phase 3, FDA Review]		
	Atopic Dermatitis	[Progress bar: Preclinical]	[Progress bar: Phase 1, Phase 2, Phase 3, FDA Review]			
<p><b>Oxybutynin/Pilocarpine (DMVT-504)</b> An oral combination of an immediate-release muscarinic antagonist with a delayed-release muscarinic agonist</p>	Primary Focal Hyperhidrosis	[Progress bar: Preclinical]	[Progress bar: Phase 1, Phase 2, Phase 3, FDA Review]			
<p><b>DMVT-503</b> A novel mechanism of action for the topical treatment of acne vulgaris</p>	Acne Vulgaris	[Progress bar: Preclinical]	[Progress bar: Phase 1, Phase 2, Phase 3, FDA Review]			



1-8-DERMAVANT (1-833-762-8268)

**Company locations:**

**Long Beach, California Office**  
Dermavant Sciences, Inc.  
3780 Kilroy Airport Way, Suite 250  
Long Beach, CA 90806

**Dallas, Texas Office**  
Dermavant Sciences, Inc.,  
2102 E. State Hwy. 114, Suite  
217, Southlake, Texas 76092

**Raleigh-Durham, North Carolina Office**  
Dermavant Sciences, Inc.  
3300 Paramount Parkway, Suite 150  
Morrisville, NC 27560

**Basel, Switzerland Office**  
Dermavant Sciences GmbH  
Viaduktstrasse 8  
4051 Basel



© 2022 Dermavant Sciences, Inc.  
All rights reserved. All trademarks are the property of Dermavant Sciences, GmbH.